PMID- 12647367
OWN - NLM
STAT- MEDLINE
DCOM- 20030417
LR  - 20171116
IS  - 0070-4113 (Print)
IS  - 0070-4113 (Linking)
VI  - 86
DP  - 2002
TI  - [HER-2 and TOP 2A gene amplifications in urinary bladder carcinoma].
PG  - 176-83
AB  - The HER-2/neu gene is frequently amplified in bladder cancer. Topoisomerase 2 
      Alpha (TOP2A) which is located nearby the HER-2/neu gene is an important 
      molecular target for several anti cancer drugs. The frequency of TOP2A 
      amplification in urinary bladder cancer is unknown. It was the aim of this study 
      to determine the frequency of HER-2 and TOP2A amplification in urinary bladder 
      cancer and to evaluate the association of these amplifications with tumor 
      phenotype. For this purpose a tissue microarray containing 768 pTa, 425 pT1 and 
      571 pT2-4 carcinomas was analyzed by fluorescence in situ hybridization (FISH). 
      Amplifications of both genes were significantly associated with advanced tumor 
      stage and high grade. HER-2 amplification was found in 1.6% of pTa, 7.2% of pT1 
      and 13.8% of pT2-4 carcinomas (p < 0.0001). HER-2 amplification was present in 
      only 1.1% of grade 1 and 0.8% of grade 2 tumors but in 14.2% of grade 3 tumors (p 
      < 0.0001). TOP2A amplification was present in 0.7% pTa, 1.8% pT1 and 3.4% pT2-4 
      carcinomas (p < 0.0001). TOP2A was found in none of the grade 1, in 0.2% of grade 
      2 and 3.8% of grade 3 tumors (p < 0.0001). 1% of all analyzed tumors had 
      simultaneously high level amplification of TOP2A and HER-2. Amplification of both 
      genes were significantly associated with tumor specific survival if all tumors 
      were analyzed together. Given the high frequency of HER-2 amplification in 
      urinary bladder cancer, some of these tumors may respond favorable to Herceptin 
      therapy. The TOP2A amplification status may influence response to anthracyclin 
      treatment.
FAU - Simon, R
AU  - Simon R
AD  - Institut fur Pathologie und Urologische Klinik, Universitat Basel, Schweiz.
FAU - Atefy, R
AU  - Atefy R
FAU - Wagner, U
AU  - Wagner U
FAU - Forster, T
AU  - Forster T
FAU - Fijan, A
AU  - Fijan A
FAU - Bruderer, J
AU  - Bruderer J
FAU - Wilber, K
AU  - Wilber K
FAU - Mihatsch, M J
AU  - Mihatsch MJ
FAU - Gasser, T
AU  - Gasser T
FAU - Sauter, G
AU  - Sauter G
LA  - ger
PT  - Journal Article
PT  - Review
TT  - HER-2 und TOP 2A Genamplifikationen beim Harnblasenkarzinom.
PL  - Germany
TA  - Verh Dtsch Ges Pathol
JT  - Verhandlungen der Deutschen Gesellschaft fur Pathologie
JID - 7503704
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Antigens, Neoplasm
MH  - DNA Topoisomerases, Type II/*genetics
MH  - DNA-Binding Proteins
MH  - Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Urinary Bladder Neoplasms/enzymology/*genetics
RF  - 36
EDAT- 2003/03/22 04:00
MHDA- 2003/04/18 05:00
CRDT- 2003/03/22 04:00
PHST- 2003/03/22 04:00 [pubmed]
PHST- 2003/04/18 05:00 [medline]
PHST- 2003/03/22 04:00 [entrez]
PST - ppublish
SO  - Verh Dtsch Ges Pathol. 2002;86:176-83.